Garman Lori, Smith Kenneth, Muns Emily E, Velte Cathy A, Spooner Christina E, Munroe Melissa E, Farris A Darise, Nelson Michael R, Engler Renata J M, James Judith A
Oklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, Oklahoma, USA.
Oklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA.
Clin Vaccine Immunol. 2016 Aug 5;23(8):664-71. doi: 10.1128/CVI.00092-16. Print 2016 Aug.
Although the U.S. National Academy of Sciences concluded that anthrax vaccine adsorbed (AVA) has an adverse event (AE) profile similar to those of other adult vaccines, 30 to 70% of queried AVA vaccinees report AEs. AEs appear to be correlated with certain demographic factors, but the underlying immunologic pathways are poorly understood. We evaluated a cohort of 2,421 AVA vaccinees and found 153 (6.3%) reported an AE. Females were more likely to experience AEs (odds ratio [OR] = 6.0 [95% confidence interval {CI} = 4.2 to 8.7]; P < 0.0001). Individuals 18 to 29 years of age were less likely to report an AE than individuals aged 30 years or older (OR = 0.31 [95% CI = 0.22 to 0.43]; P < 0.0001). No significant effects were observed for African, European, Hispanic, American Indian, or Asian ancestry after correcting for age and sex. Additionally, 103 AEs were large local reactions (LLRs), whereas 53 AEs were systemic reactions (SRs). In a subset of our cohort vaccinated 2 to 12 months prior to plasma sample collection (n = 75), individuals with LLRs (n = 33) had higher protective-antigen (PA)-specific IgE levels than matched, unaffected vaccinated individuals (n = 50; P < 0.01). Anti-PA IgE was not associated with total plasma IgE, hepatitis B-specific IgE, or anti-PA IgG in individuals who reported an AE or in matched, unaffected AVA-vaccinated individuals. IP-10 was also elevated in sera of individuals who developed LLRs (P < 0.05). Individuals reporting SRs had higher levels of systemic inflammation as measured from C-reactive protein (P < 0.01). Thus, LLRs and SRs are mediated by distinct pathways. LLRs are associated with a vaccine-specific IgE response and IP-10, whereas SRs demonstrate increased systemic inflammation without a skewed cytokine profile.
尽管美国国家科学院得出结论,吸附炭疽疫苗(AVA)的不良事件(AE)情况与其他成人疫苗相似,但30%至70%接受询问的AVA疫苗接种者报告有不良事件。不良事件似乎与某些人口统计学因素相关,但潜在的免疫途径却知之甚少。我们评估了一组2421名AVA疫苗接种者,发现153人(6.3%)报告有不良事件。女性更易出现不良事件(优势比[OR]=6.0[95%置信区间{CI}=4.2至8.7];P<0.0001)。18至29岁的个体比30岁及以上的个体报告不良事件的可能性更小(OR=0.31[95%CI=0.22至0.43];P<0.0001)。在校正年龄和性别后,未观察到非洲、欧洲、西班牙裔、美洲印第安或亚洲血统有显著影响。此外,103例不良事件为严重局部反应(LLR),而53例不良事件为全身反应(SR)。在我们队列中于采集血浆样本前2至12个月接种疫苗的一个亚组(n=75)中,出现严重局部反应的个体(n=33)的保护性抗原(PA)特异性IgE水平高于匹配的未受影响的接种个体(n=50;P<0.01)。在报告有不良事件的个体或匹配的未受影响的AVA疫苗接种个体中,抗PA IgE与总血浆IgE、乙肝特异性IgE或抗PA IgG均无关联。出现严重局部反应的个体血清中的IP-10也升高(P<0.05)。报告有全身反应的个体从C反应蛋白测量的全身炎症水平更高(P<0.01)。因此,严重局部反应和全身反应由不同途径介导。严重局部反应与疫苗特异性IgE反应和IP-10相关,而全身反应表现为全身炎症增加且细胞因子谱无偏差。